Haustein K O, Hentschel H, Kaiser B
Int J Clin Pharmacol Ther Toxicol. 1980;18(8):352-6.
In 25 digitalized patients with ischaemic heart disease who had survived a myocardial infarction for 2 to 4 weeks, the systolic time intervals (STI) and changes of glycoside plasma level were measured before and up to 5 hrs after oral intake of a maintenance dose of digitoxin (n = 18) or of digoxin (n = 7). Between the changes of STI and the increase in digitoxon and digoxin plasma level no significant correlations were found. Therefore it is concluded that neither shortening of STI during the test period nor PEP/LVET are reliable criteria of individualizing and optimizing the therapy with cardioactive glycosides.
在25例患有缺血性心脏病且心肌梗死存活2至4周的数字化患者中,在口服维持剂量地高辛(n = 18)或洋地黄毒苷(n = 7)之前及之后长达5小时,测量收缩期时间间期(STI)和糖苷血浆水平变化。未发现STI变化与地高辛和洋地黄毒苷血浆水平升高之间存在显著相关性。因此得出结论,在测试期间STI缩短或PEP/LVET均不是个体化和优化强心苷治疗的可靠标准。